← All trials
NCT05381194
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 13, 2022
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2027
- First posted
- May 19, 2022
- Last posted
- Mar 15, 2024
- Enrollment
- 80
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of UlsanLead sponsor
- Seoul National UniversityCollaborator
- Seoul National UniversityCollaborator
- University of UlsanSponsor investigator
- Soon Chun Hyang UniversityCollaborator
- Incheon St.Mary's HospitalCollaborator
- Sungkyunkwan UniversityCollaborator
- Chonnam National UniversityCollaborator
- Chonbuk National UniversityCollaborator
- Catholic University of KoreaCollaborator
- Pusan National UniversityCollaborator
- Yonsei UniversityCollaborator
- Dongguk UniversityCollaborator
- University of UlsanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.